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Multicore Liquid Perfluorocarbon-Loaded Multimodal 
Nanoparticles for Stable Ultrasound and 19F MRI Applied 
to In Vivo Cell Tracking
Olga Koshkina, Guillaume Lajoinie, Francesca Baldelli Bombelli, Edyta Swider,  
Luis J. Cruz, Paul B. White, Ralf Schweins, Yusuf Dolen, Eric A. W. van Dinther,  
N. Koen van Riessen, Sarah E. Rogers, Remco Fokkink, Ilja K. Voets, Ernst R. H. van Eck, 
Arend Heerschap, Michel Versluis, Chris L. de Korte, Carl G. Figdor, I. Jolanda M. de Vries,  
and Mangala Srinivas*
Ultrasound is the most commonly used clinical imaging modality. However, 
in applications requiring cell-labeling, the large size and short active lifetime 
of ultrasound contrast agents limit their longitudinal use. Here, 100 nm 
radius, clinically applicable, polymeric nanoparticles containing a liquid 
perfluorocarbon, which enhance ultrasound contrast during repeated 
ultrasound imaging over the course of at least 48 h, are described. The 
perfluorocarbon enables monitoring the nanoparticles with quantitative  
19F magnetic resonance imaging, making these particles effective multimodal 
imaging agents. Unlike typical core–shell perfluorocarbon-based ultrasound 
contrast agents, these nanoparticles have an atypical fractal internal 
structure. The nonvaporizing highly hydrophobic perfluorocarbon forms 
multiple cores within the polymeric matrix and is, surprisingly, hydrated 
with water, as determined from small-angle neutron scattering and nuclear 
magnetic resonance spectroscopy. Finally, the nanoparticles are used to 
image therapeutic dendritic cells with ultrasound in vivo, as well as with  
19F MRI and fluorescence imaging, demonstrating their potential for  
long-term in vivo multimodal imaging.
DOI: 10.1002/adfm.201806485
1. Introduction
Imaging modalities, such as magnetic 
resonance imaging (MRI), single photon 
emission computed tomography (SPECT), 
and positron emission tomography (PET) 
are key players in personalized medi-
cine, due to their noninvasive nature.[1] 
However, these imaging techniques are 
expensive, logistically difficult, and can 
involve ionizing radiation, all of which 
hinder their longitudinal and frequent 
use. Ultrasound does not suffer from 
these limitations and can be used at the 
bedside, with frequent time intervals, and 
provide real-time imaging with excellent 
resolution. Consequently, ultrasound has 
become the most widespread and cost-
effective clinical imaging modality.
Ultrasound has, so far, been largely 
unsuitable for longitudinal applications, 
such as cell tracking, where labeling with 
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a contrast agent is needed, mainly because of the absence of 
effective contrast agents with sufficient in vivo lifetime.[2] 
These agents are typically micrometer-sized, surfactant (mainly 
phospholipid)-coated microbubbles with a compressible gas 
core.[3] Microbubbles are rapidly cleared from the circulation, 
within minutes, by trapping in the lungs and liver, by acoustic 
destruction, or by deflation as a result of gas diffusion. Several 
modifications of microbubble formulations have been proposed 
to overcome the stability issues, which mainly focused on shell 
composition, in order to increase the circulation time and dura-
bility of the microbubble agents.[4] Examples of these modifica-
tions include the combination of different shell compositions, 
like albumins, phospholipids, or polymers[5] with different gas-
eous cores, such as high mole cular weight gases, for example, 
perfluorocarbon (PFC, C3F8 or C4F10) or sulfur hexafluoride 
(SF6).[6] Nevertheless, none of these attempts resulted in an in 
vivo stability exceeding 1 h. Additionally, the large size of these 
agents (typically 2 µm) prevents extravasation and can effec-
tively limit intracellular localization.
Sub-micrometer droplets[5] consisting of liquid PFCs are able 
to extravasate and were proposed as phase-change agents that 
can be vaporized with an acoustic trigger and subsequently 
generate contrast.[7–11] The droplet-to-bubble conversion upon 
vaporization, comes with a fivefold increase in diameter.[12] Both 
microbubbles and phase-change droplets have been used to tem-
porarily disrupt cell membranes and form pores that allow the 
uptake of specific drugs (sonoporation).[4,13–15] However, the high 
acoustic pressures needed to reach the vaporization threshold of 
these phase-change droplets and the  short-lived contrast gen-
eration capability of the transient microbubbles resulting from 
acoustic vaporization remain an issue for long-term monitoring 
with ultrasound, making cell labeling infeasible.
Liquid PFCs typically generate poor ultrasound contrast[16] 
unless very high concentrations are used.[17–20] PFCs are both 
extremely hydrophobic and lipophobic, and stabilization of 
these compounds in aqueous environments is challenging. 
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Typically, PFCs used in vivo as a lipid-stabilized emulsion 
have limited stability.[21] All imaging agents described thus 
far that contain a liquid PFC have a core-shell-like structure, 
where the liquid PFC droplet is coated with a lipid or polymer 
shell. A significant improvement of stability can be achieved 
by the encapsulation of PFCs in inorganic shells, such as 
silica.[22,23] However, while well-suited for in vivo applica-
tions, these materials still have to pass approval for clinical 
use. Despite the stability improvements and excellent acoustic 
properties, current clinical ultrasound contrast agents are still 
one-shot contrast agents, ill-suited for long-term applications, 
such as cell tracking or long-term labeling and imaging of 
inflamed tissue. Shapiro et al. recently introduced a new class 
of reporters for ultrasound, based on genetically encoded gas 
nanostructures from microorganisms. These gas-filled protein 
nanostructures allow the possibility of imaging of targets out-
side the vasculature and monitoring of cellular signals such 
as gene expression.[24–26] A few other studies describe the use 
of PFC-free solid silica-based nanoparticles for in vivo moni-
toring of stem cells with ultrasound and MRI.[27–29] These 
nanoparticles form solid aggregates upon cellular uptake 
under physiological conditions and allow the imaging and 
tracking of human mesenchymal stem cells with ultrasound 
due to the large size of aggregates.[29] The application of these 
materials is likely limited in applications that require colloi-
dally stable particles.
Here, we present nanoparticles that consist of a high- 
boiling-point liquid PFC, encapsulated in a poly(lactic- 
 co-glycolic acid) (PLGA) matrix.[30] These nanoparticles are stable 
in ultrasound over a timeframe of days, including after exposure 
to extremely high-pressure ultrasound. With a radius of 100 nm, 
these particles are small enough for cell uptake, and to extrava-
sate and leave the circulation. The nanoparticles are loaded with 
perfluoro-15-crown-5-ether (PFCE) to enable imaging with both 
ultrasound and 19F MRI. Additionally, these nanoparticles can 
be loaded with gadoteridol for 1H MRI imaging and with fluo-
rescent dyes. PFC-loaded PLGA nanoparticles have been origi-
nally explored as imaging agents for 19F MRI.[31–33] 19F MRI has 
become a key player in cell tracking, owing to (1) the absence of 
radiotracers and ionizing radiation, (2) an imaging window not 
restricted by tracer decay, (3) the ability for in vivo quantifica-
tion, and (4) the direct clinical translatability.[34–36] On the other 
hand, MRI and, in particular 19F MRI, can be slow and cum-
bersome, and therefore a combination with a bedside technique, 
such as ultrasound, is highly valuable, as it allows for an optimal 
combination of quick imaging with ultrasound for localization, 
followed by single time point 19F MRI for quantification.
We investigate these PFCE-PLGA nanoparticles for long-
term ultrasound imaging, focusing on cell tracking for cell 
therapy applications. We first characterize the internal structure 
of the nanoparticles using nuclear magnetic resonance spec-
troscopy (NMR) and small angle neutron scattering (SANS). 
These analyses reveal that the nanoparticles have a fractal 
 multicore structure. Next, we imaged free nanoparticles and 
nanoparticle-loaded cells, both in vitro using phantoms and in 
vivo in mice, using multimodal imaging (ultrasound, 19F MRI, 
and fluorescence). We show that the nanoparticles are stable 
upon ultrasound exposure, fully biocompatible, and applicable 
to in vivo cell tracking.
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2. Results and Discussion
2.1. Nanoparticles Display Long-Term Stable Acoustic Contrast
The nanoparticles are synthesized using a miniemulsion 
formulation technique.[31,33] They consist of a PLGA matrix 
loaded with PFCE and are stabilized with poly(vinyl alcohol) 
(PVA) (Figure 1a). Further modifications such as fluorescent 
dye or 1H MR imaging agent (typically gadoteridol) can be 
carried out, if needed. The nanoparticles have a mean radius 
of about 100 nm, as shown by cryogenic scanning electron 
microscopy (SEM, Figure 1b, radius 100 ± 20 nm (N = 20)). 
A PFCE encapsulation of 20–40 wt% (33 ± 11 wt% (number 
of batches N = 79)) was demonstrated by NMR spectroscopy 
(compare Table S2, Supporting Information, for some exam-
ples). We found that these nanoparticles, apart from being 
suitable for 19F MRI,[31,33] also generate acoustic contrast and 
can be imaged using standard ultrasound B-mode imaging 
(Figure 1c). Moreover, the acoustic contrast lasts at least a few 
hours with no signs of degradation, allowing for long-term 
imaging over a course of 48 h at least, as we show later in this 
study (Figure 2c).
To demonstrate that PFCE-loaded PLGA nanoparticles can 
be used for long-term ultrasound imaging, we carried out sev-
eral in vitro experiments. First, we exposed the nanoparticles 
to ultrasound for 60 s and compared the diameter before and 
after ultrasound exposure using dynamic light scattering (DLS, 
Figure 2a). Next, we imaged the nanoparticles with SEM before 
and after probe sonication (Figure 2b). Both techniques dem-
onstrated that the particles radius does not change indicating 
nanoparticle stability. The PFCE content also did not change 
after insonation. Thus, exposure to ultrasound did not signifi-
cantly alter the properties of these nanoparticles.
To assess the stability of acoustic contrast in biological condi-
tions, we injected nanoparticles in a tissue sample and imaged 
using a clinical ultrasound scanner at room temperature 
(Figure 2c) at high and low mechanical index (MI). After the 
first imaging session, the transducer was left “on” continuously 
for 80 min at high MI (MI = 1.2). This exposure was then fol-
lowed by another imaging session at both MI values (Figure 2c). 
The sample was then frozen for 48 h and thawed to room tem-
perature before imaging again. Even after this freezing and 
thawing of the sample, we observed no visible decrease in 
contrast, demonstrating that the imaging agents are extremely 
stable. Furthermore, the long stability of contrast strongly sug-
gests the absence of gaseous components that could have come 
from gas diffusion or vaporization of the PFCE itself.
An ideal ultrasound contrast agent is characterized by a high 
scattering cross section and a low absorption of sound waves. 
The mechanical response of ultrasound contrast of micro-
bubbles can be recorded with ultra-high-speed imaging.[37] 
However, the size of these PFCE-PLGA nanoparticles is well 
below the optical diffraction limit and necessitates alternative 
and more indirect methods to quantify their acoustic proper-
ties. For both microbubbles and solid particles, the scattering 
cross section is closely related to the attenuation cross section. 
Therefore, we measured acoustic attenuation of PFCE-loaded 
nanoparticles, using nanoparticles loaded with perfluorooctylb-
romide (PFOB) as control, both with and without  gadoteridol. 
The characteristics of nanoparticles used for attenuation meas-
urements are summarized in Table S1 (Supporting Informa-
tion). Acoustic attenuation through nanoparticle solutions 
was measured at frequencies ranging from 3.5 to 8 MHz and 
pressures ranging from 50 kPa to 1 MPa (Figure 3a). These dif-
ferent pressures resulted in the error bars in Figure 3a. PFCE-
PLGA nanoparticles showed the highest attenuation over the 
entire frequency range. This measurement, however, is not a 
direct measurement of the scattering properties of the parti-
cles, in particular because different mechanisms can affect the 
attenuation of dispersions.[38] To further assess the scattering 
properties of PFCE-PLGA nanoparticles, an additional meas-
urement was performed. Here, we studied the displacement of 
the particles induced by acoustic radiation force, which can be 
more directly linked to the scattering cross section of the parti-
cles. Nanoparticle suspensions were injected in a microchannel 
subjected to an ultrasound standing wave (Figure 3b). Under 
the effect of primary acoustic radiation force, the particles move 
toward the node or the antinode of the standing wave.[39] The 
displacement of Sonovue(c) microbubbles was used to quantify 
the pressure field in the capillary. The amplitude of the acoustic 
radiation force (Figure 3c) was determined from a simple force 
balance, and the scattering cross section was subsequently cal-
culated from radiation force as described in the Experimental 
Section. The theoretical scattering cross section[40] of microbub-
bles as a function of their size at a driving frequency of 2.0 MHz 
is depicted by the dashed blue line. The scattering coefficient 
of the perfluorooctane (PFO) and PFOB nanoparticles, used 
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Figure 1. a) Chemical structures of the main components of PFCE-
loaded PLGA nanoparticles: PLGA, PFCE, and PVA. Fluorescent dyes, or 
a Gd-based MR contrast agent, such as gadoteridol, can be further added 
for multimodal imaging. b) Cryo-SEM image of nanoparticles in water 
shows an average radius of 100 ± 20 nm. cNP = 10 mg mL−1. Scale bar: 
1 µm. c) Ultrasound image of aqueous solution of nanoparticles (right) in 
a gelatin phantom compared to ultrapure water (left). cNP = 10 mg mL−1, 
21 MHz, 50 dB.
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as controls, was similar to that expected for a coated bubble 
of comparable size. Interestingly, PFCE nanoparticles dis-
play a scattering coefficient that is two orders of magnitude 
higher than the predicted coefficient for a bubble of the same 
diameter. PFCE does not only improve echogenicity of nano-
particles but also changes the direction of the radiation force 
(Figure 3b): PFCE-loaded nanoparticles move toward the pres-
sure antinode (upper panel), as expected for small bubbles. In 
contrast, nanoparticles loaded with other PFCs move toward 
the pressure node. This effect was detected at very low pres-
sures (50 kPa), that is, in the absence of acoustic streaming and 
of spontaneous bubble formation from the PFCE. The latter is 
also excluded by the fact that the nanoparticles do not lose their 
echogenicity even after the application of high-intensity ultra-
sound, including tip sonication, or freeze/thaw procedures.
Overall, PFCE-loaded nanoparticles display sufficient acoustic 
contrast combined with long-term stability, up to several days 
in phantom, and thus are suitable for longitudinal imaging 
with ultrasound. The scattering cross section of PFCE-PLGA 
nanoparticles was lower compared to micrometer-sized micro-
bubbles, as can be seen, for example, from the simulation of the 
scattering cross section of microbubbles in Figure 3c. However, 
their extraordinary high stability, small size, and the ease of 
loading with further compounds allow for different applications 
compared to microbubbles. Especially, applications that require 
extravasation or long-term monitoring of contrast agent, such 
as targeted drug delivery or cellular therapy, should be possible 
using the nanoparticles in the future.
2.2. PFCE-PLGA Nanoparticles Have a Fractal 
Multicore Structure
To explain the atypical stability and acoustic properties of 
PFCE-PLGA nanoparticles, we further investigated them by 
extensive physicochemical analyses. Particularly, we focused 
Adv. Funct. Mater. 2019, 29, 1806485
Figure 2. PLGA-PFCE nanoparticles are stable in ultrasound. a) Number distributions of nanoparticles radius before (straight line) and after (dashed 
line) exposure to ultrasound measured at 173°. No changes were observed. Three different batches of nanoparticles were used (PFCE content NP1 
24 wt%, NP2 and NP3 both 38 wt%; NP = nanoparticle). Each line represents an average of two independent measurements. b) SEM images were 
acquired on nanoparticles before (upper panel) and after (lower panel) probe sonication. No changes were observed in particle morphology. NPs with 
39 wt% PFCE and hydrodynamic radius of 96 nm diameter (measured by DLS at 173°) were used. c) 0.5 mg of PFCE nanoparticles were injected in 
tissue (liver) and imaged at 0 and 80 min and 48 h postinjection at MI values of 0.2 and 1.2 (boxes indicate location of the particles). The transducer 
was left “on” continuously at MI = 1.2 in the same position for 80 min after injection. The sample underwent a freeze/thaw cycle before the 48 h time 
point. The SNR did not change for each MI over the period of 48 h.
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on potential differences in the structural configuration, which 
could result in the observed differences in contrast capability. 
As a reference, we synthesized PFCE-loaded core–shell PLGA 
nanocapsules (Figure 4a). To prepare these nanocapsules, we 
modified the procedure described previously by Tsapis et al. 
for the preparation of PFOB-loaded core–shell nanocapsules.[41] 
Adv. Funct. Mater. 2019, 29, 1806485
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Figure 3. Acoustic characterization of PFCE-PLGA nanoparticles. a) Attenuation of acoustic waves by nanoparticle solution (10 mg mL−1) at different 
frequencies. PFCE-loaded nanoparticles display higher attenuation than PFOB-loaded nanoparticles indicating that PFCE nanoparticles display higher 
scattering intensity. Each line represents an independent batch of nanoparticles; number of the batch corresponds to number in Table S1 (Supporting 
Information). b) Optical maximum intensity projection images for a sample of PFCE particles (upper) and PFOB particles (lower) flowing in a channel 
exposed to a standing acoustic wave. PFCE particles move toward high-pressure areas (channel edges indicated) whereas the PFOB particles move 
toward the pressure nodes located at the center of the channel. A sample path is highlighted in each panel. c) Scattering cross section of various 
particles compared to coated bubbles, as a function of the size of the particles. A square symbol denotes a positive sign for the radiation force, while 
circles denote a negative sign. Nanoparticles with PFCE show unexpectedly high scattering cross sections.
Figure 4. Characterization of the nanoparticles and the core–shell capsules with SANS using contrast variation method. a) Schematic representation of 
core–shell capsules as they are “seen” by neutrons based on their scattering length density (SLD) in solvents used for SANS measurements. In D2O, 
both PLGA and PFCE contribute to scattering contrast, while in H2O/D2O 36/64 (v:v) or in H2O/D2O 61/39 (v:v) either PFCE (SLD = 3.86 × 10−6 Å−2) or 
PLGA (SLD = 2.11 × 10−6 Å−2) have the same scattering density as the solvent and are matched. b) SANS scattering patterns of PFCE-loaded core–shell 
capsules with fits of experimental data to core–shell structure. The form factor of nanocapsules can be fitted with a core–shell model (black lines). 
c) Schematic representation of the fractal core–shell model, which was used to fit the SANS data of nanoparticles. The scattering intensity of nano-
particles results from core–shell form factor, which is multiplied with a fractal structure factor to account for multiple domains within one particle. 
PFCE represented by red spheres, PLGA black lines, PVA blue lines. Rg is the radius of gyration. Note that the drawing of Rg is approximate; Rg is the 
root-mean-square distance of the parts of an object from its center of mass). d) SANS scattering patterns of PFCE-loaded nanoparticles with fits of 
the scattering intensity with a fractal model from (b) in different solvents. In D2O and H2O/D2O, 36/64 (v:v) (black lines) fractal core–shell model was 
used, while in H2O/D2O 61/39 (v:v) we applied the model for fractal aggregates with spherical building blocks (blue line).
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Thus, it could be expected that PFCE-loaded colloids will have 
a core–shell geometry, similar to PFOB-loaded colloids from 
the literature. In this method, sodium cholate, which is a small 
anionic surfactant, is used to stabilize the emulsion droplets 
during the emulsion formation, instead of nonionic poly(vinyl 
alcohol). After evaporation of the solvent, nanocapsules were 
coated with poly(vinyl alcohol) by adsorption.[41] In contrast 
to the nanoparticles, which are stable in solution for several 
days,[31] PFCE-loaded core–shell capsules displayed lower col-
loidal stability with the formation of visible aggregates after 
several hours, potentially as a consequence of coalescence or 
Ostwald ripening.[42] Similar to PFOB-loaded capsules from ref-
erence,[43] PFCE-loaded capsules showed ultrasound contrast in 
harmonic mode (Figure S10, Supporting Information).
To determine the internal structure of both types of PFCE-
loaded colloids, we first measured transmission electron micros-
copy (TEM) and cryo-TEM. However, nanoparticles displayed 
only low contrast and were not stable in the electron beam. 
Therefore, we decided to use SANS, as it enables determination 
of internal structure of colloids in the solution. SANS experi-
ments were performed with nanoparticles prepared with and 
without addition of gadoteridol (results in Figure 4 or the Sup-
porting Information, respectively), as an additional 1H MR con-
trast agent, and core–shell nanocapsules. The summary of char-
acterization of the nanocapsules and of the nanoparticles from 
Figure 4 with other techniques are in the Supporting Informa-
tion (Table S3, Supporting Information; cryo-SEM images in 
Figures S2 and S3, Supporting Information; static light scat-
tering (Guinier plots) in Figure S1, Supporting Information).
To determine the internal structure of nanoparticles by SANS, 
we applied a contrast variation method. In this technique, the 
neutron scattering contrast of the solvent is adjusted to high-
light different compartments of nanoparticles.[44] A measure 
for the scattering contrast of the material is its scattering length 
density (SLD), which depends on the atomic composition and 
bulk density of the compound (Table S2, Supporting Informa-
tion). As light water (H2O) and heavy water (D2O) have different 
scattering length densities, it is possible to match a specific com-
partment of the particles using a H2O/D2O mixture, which has 
the same SLD as the compartment. Thus, the matched compart-
ments seem transparent for neutrons, as their scattering is the 
same as of the solvent background. Here, we used a H2O/D2O 
36/64 (v:v) mixture to match PFCE (SLD = 3.87 × 10−6 Å−2) and 
H2O/D2O 61/39 (v:v) to match PLGA (SLD = 2.11 × 10−6 Å−2), 
while in D2O both components contributed to particle scat-
tering. Figure 4a shows a schematic of how different compo-
nents are “seen” by neutrons in different solvents.
The resulting SANS patterns of nanoparticles (with gadoter-
idol) and nanocapsules are shown in Figure 4b,d, nanoparticles 
without gadoteridol in Figure S6 (Supporting Information) and of 
non-loaded PLGA nanoparticles, which we used as an additional 
control in Figure S4 (Supporting Information) (compare Table S3, 
Supporting Information, and cryo-SEM images in Figures S2 and 
S3, Supporting Information, for further details on used samples). 
To determine the internal structure from SANS scattering pat-
terns, we modeled the q-dependent absolute scattering intensities 
using theoretical models comprising particle form factors P(q) 
for the scattering of different geometrical shapes. The scattering 
profiles of the nanocapsules could be modeled with a core–shell 
structure, as expected (Figure 4b, Table S4, Supporting Informa-
tion). By contrast, neither a core–shell model nor a homogeneous 
sphere model, which we used for nonloaded PLGA nanoparticles, 
matches well with the scattering pattern of PFCE-loaded nanopar-
ticles. Instead, a model that describes a particle as a fractal aggre-
gate of core–shell building blocks with a PFCE core and PLGA 
shell provided a good fit of the experimental SANS patterns.[45] A 
schematic representation of the model is shown in Figure 4b, the 
SANS patterns with the resulting model fit in Figure 4d, and the 
fit results are further summarized in Table S5 (Supporting Infor-
mation). According to this fractal model, the small core–shell 
building blocks have a PFCE core radius of 9 nm and PLGA shell 
with a thickness of 4 nm. These building blocks are then assem-
bled into a fractal multicore particle, which has a radius of gyra-
tion, Rg, of 98 nm (calculated from the fractal model as described 
by Teixeira).[45] Thus, the radius of gyration from model analysis 
is similar to the radius of 100 nm obtained from cryo-SEM fur-
ther confirming the SANS model. Note, that Rg and radius from 
cryo-SEM measurement are not the same radius, as Rg is defined 
as the root-mean-square distance of the parts of an object from 
its center of mass. Further characterization of the samples from 
SANS with static and dynamic light scattering and cryo-SEM 
and the discussion of the results are presented in Section S1.2 
(Supporting Information). SANS scattering patterns of PFCE 
nanoparticles prepared without addition of 1H MR contrast 
agent gadoteridol (Figure S6, Table S7, Supporting Information) 
showed similar results, suggesting that addition of gadoteridol 
did not affect the internal structure. This could be due to low 
encapsulation of gadoteridol. Additional SANS data comparing 
different batches of nanoparticles are available from the authors.
The fractal model agreed with experimental scattering pat-
terns of nanoparticles only when the SLD of the PLGA core and 
PFCE shell were not fixed to the values of the pure compounds, 
but instead treated as free fitting parameters and calculated 
from the model. The resulting SLD values were between the 
SLD of pure compound and the solvent suggesting that both 
PLGA and PFCE are hydrated with the solvent used for SANS 
measurement (Table S5, Supporting Information). Similar 
results were obtained for several samples at two different SANS 
beamlines (see Figure S6, Table S6, Supporting Information, 
for results on a different sample).
To prove that the highly hydrophobic PFCE is hydrated, 
we used NMR spectroscopy. First, we carried out relaxation 
time measurements at different temperatures with solid-state 
NMR spectroscopy (ssNMR) using the nanoparticles either as 
a freeze-dried powder or swollen with water. Here, the hydra-
tion of nanoparticles leads to a decrease of the spin-lattice 
relaxation time (T1) and an increase of the spin-spin relaxation 
time (T2) (Figure 5a and Figure S7, Supporting Information). 
These changes indicate that water is inside the polymer net-
work making it more flexible, and thus, suggesting that water 
could be close to PFCE. Moreover, heteronuclear Overhauser 
enhancement spectroscopy (HOESY) measurements of fractal 
nanoparticles in solution also revealed that water is in close con-
tact with PFCE cores (Figure 5b; tirifluoroacetic acid (TFA) as 
internal reference (δ − 76 ppm)). Nanoparticles show an HOE 
cross-peak between 19F nucleus in PFCE (−92 ppm) and 1H 
nucleus in water (4.79 ppm). The HOE effect is caused by cross-
space dipole–dipole interaction and observed only when the 
Adv. Funct. Mater. 2019, 29, 1806485
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internuclear distance is lower than a few Angstrom, and when 
the interaction is long-lived. Such interaction between water and 
PFCE is unexpected, as PFCE is highly hydrophobic. In contrast 
to nanoparticles, the HOE in PFCE core–shell nanocapsules, 
which were used as a control, is very low (Figure 5c). This result 
is also in accord with SANS measurements, where the SLD of 
PFCE–core in the capsules could be fitted with a value of pure 
PFCE. Also, the HOE of the internal TFA-reference appears 
lower in nanocapsules than in nanoparticles, indicating that 
TFA could also diffuse inside the nanoparticles, as discussed fur-
ther in the Supporting Information (Figure S8, Table S8, Discus-
sion S2, Supporting Information). HOESY measurements were 
reproduced several times with different batches of nanoparticles 
and nanocapsules showing the same result. The measurements 
shown in Figure 5b,c were done with different samples than 
those used for SANS measurements, as these were measured 
using exactly the same settings with TFA as internal reference. 
HOE was also observed in samples that were measured with 
SANS (data not shown, but available from the authors).
Overall, SANS and NMR revealed that PFCE-PLGA nano-
particles have a multicore structure in which the highly hydro-
phobic PFCE is hydrated. The formation of multiple PFC 
domains has been reported previously in multicore micelles 
made of thermoresponsive polymers with covalently attached 
perfluorocarbon side chains,[46,47] where PFC side chains cluster 
due to the hydrophobic interaction. However, the noncovalent 
encapsulation of liquid perfluorocarbons in polymeric parti-
cles usually results in core–shell structures. Furthermore, the 
HOE, which results from dipole–dipole interactions between 
fluorocarbon and water, is completely unexpected for highly 
hydrophobic materials and has not reported previously. Thus, 
our results indicate that not only hydrophobic interactions but 
also other effects could play a role in the formation of multicore 
structure. Though it appears surprising that PFCE is close to 
water in the nanoparticles, it is known that PFCE can form com-
plexes with some anions in the gas phase[48,49] and also weak 
complexes with cations.[50] The strong electron-withdrawing 
nature of fluorine could possibly be the reason for the occur-
rence of HOE effect. The fractal structure is obtained only with 
PVA as a surfactant, and the use of sodium cholate during the 
emulsification leads to core–shell structures. Though the PVA 
content in nanoparticles could not be determined exactly, the 
presence of PVA was shown by 1H NMR (Figure S9, Supporting 
Information). These observations suggest that the surfactant 
plays a pivotal role in the formation of the structure.
The relationship between the acoustic contrast and the struc-
ture of the particles remains unclear, especially considering small 
size of the PFCE nanoparticles. Our data, especially imaging in 
phantoms up to 48 h (Figure 2c), indicate that the generation 
of acoustic contrast does not involve vaporization of PFCE. In 
contrast, commercial microbubbles, such as Sonovue(c),[51] 
can be imaged only for a short time frame. Rapoport et al. 
previously observed cavitation in polymer-stabilized PFCE 
nanodroplets and suggested the evaporation of gases, which 
are dissolved in PFCE, as a possible reason for cavitation.[7]  
Similarly, the core–shell nanocapsules, which we used as a con-
trol in this study, displayed acoustic contrast in harmonic mode 
(compare Figure S10, Supporting Information, for images on 
nanocapsules in harmonic mode). In contrast, fractal PFCE-
PLGA nanoparticles used in this study did not show harmonic 
signal but could be imaged using B mode. Additional ultra- high-
speed imaging experiments with PFCE-PLGA nano particles 
using a Brandaris128 camera also did not show cavitation or 
bubble formation (data not shown due to insufficient resolu-
tion). Though nanoparticles were too small to be resolved with 
the Brandaris128 camera, we expect that in the case of cavitation, 
micrometer-sized bubbles would be visible, similar to cavitation 
of phase-change nanodroplets.[17,52] Thus, either no cavitation 
took place or the formed bubbles were very small and condensed 
back to nanoparticles quickly, and in a reversible manner. These 
observations suggest that the mechanism of acoustic contrast 
generation might be different from phase-change nanodroplets 
and microbubbles and does not involve cavitation.
Chen et al. recently reported the acoustic manipulation of 
silver nanocubes, demonstrating that the structure of nano-
cubes plays a more important role than the size.[53] Similarly, 
the multicore structure of PFCE-PLGA nanoparticles could be 
a key to the mechanism of acoustic contrast generation. How-
ever, a detailed systematic investigation of different parameters, 
affecting the structure of the nanoparticles and their behavior 
in the acoustic field, is needed to understand the mechanism 
of acoustic contrast generation, although many standard 
acoustic characterization assays are designed for much larger 
micrometer-sized agents.
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Figure 5. Characterization of nanoparticles with solid-state NMR spectroscopy and heteronuclear Overhauser enhancement spectroscopy (HOESY). 
a) ssNMR spectroscopy: Spin-lattice relaxation time, T1, of freeze-dried nanoparticles, and of nanoparticles swollen with water reveals that water is 
present inside the nanoparticle (same batch of nanoparticles as used for SANS measurements in Figure 4d). b,c) HOESY NMR of PFCE-loaded nano-
particles (NPs prepared without gadoteridol, PFCE-content 26 wt%, Rh(173°) = 97 nm) and nanocapsules (PFCE-content 14 wt%, Rh(173°) = 82 nm) 
with TFA (δ = −76 ppm (CF3COOH)) as internal reference show that in nanoparticles 19F of PFCE is close to water.
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2.3. Nanoparticles Are Suitable for In Vivo Cell Imaging
To demonstrate that PFCE-PLGA nanoparticles are suitable for 
long-term ultrasound imaging in vivo, we performed in vivo 
imaging in mice. With this experiment, we show that PFCE-
loaded PLGA nanoparticles can be used for long-term tracking 
of therapeutic cells during cell therapy. We carried out in vivo 
imaging with a high-resolution preclinical ultrasound scanner, 
due to small size of the animals, and particularly murine 
lymph nodes (LNs) which cannot be resolved using clinical 
frequencies. The results were confirmed ex vivo with a clin-
ical ultrasound scanner to demonstrate that nanoparticles can 
be imaged at frequencies that are usually used in the clinics. 
We used primary human therapeutic dendritic cells (DCs), as 
used in clinical trials[54] for cancer therapy of immunogenic 
tumors, such as melanoma. Here, we focus on nanoparticles 
rather than capsules, due to their superior stability. We have 
previously shown that labeling cells with nanoparticles does 
not result in the loss of cell viability, when compared to a non-
labeled control.[31–33] Furthermore, our previous MRI study has 
shown no effect of labeling on cells with respect to the expres-
sion of maturation markers by DCs, their ability to activate T 
cells or their migratory behavior.[31,55] Together, no effects on 
cell function were observed. Moreover, the cellular 19F loading, 
a key parameter for 19F MR-sensitivity, is the highest reported 
so far.[21]
Here, we first injected 2 × 106 cells labeled with nano- 
particles in liver tissue and imaged the tissue with ultrasound, 
followed by fluorescence and 19F MR imaging to confirm the 
localization of the cells. We could detect the labeled cells using 
all three imaging modalities after the injection into excised liver 
tissue (Figure 6a). Note that the 19F MRI sensitivity matches the 
sensitivity reported previously,[21] as expected for liquid, rather 
than gaseous or solid, PFCE.
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Figure 6. Nanoparticles are suitable for tracking the therapeutic cells with ultrasound in vivo. a) US, fluorescence, and 1H and 19F (false color) MR 
images of 2 million DCs labeled with particles containing PFCE, IC-Green, and Gd injected in a tissue sample (boxes indicate position of the cells). 
b) High-frequency in vivo US images of the inguinal lymph node (ILN) of a mouse before (left) and after (right) intranodal injection of 0.1 mg of 
PFCE nanoparticles show a tenfold increase in mean contrast in the node after injection (see Videos S1 and S2, Supporting Information). c) Mice 
were injected with 5 million labeled primary murine DCs in the footpad and imaged after 24 h using US on a clinical scanner (Figure S9, Supporting 
Information) and a high-resolution small animal scanner (48 MHz). Control mice received an equivalent number of nonlabeled cells or free particles. 
In vivo images of the draining lymph nodes (inguinal lymph node (ILN) and popliteal lymph node (PLN)) are shown at high resolution (48 MHz). 
Ex vivo images are also shown (circled) at high and low frequency (Figure S9, Supporting Information). Labeled DCs increased contrast in the node 
nearly fivefold compared to nonlabeled cells. d) A fluorescence image shows the same results, with labeled cells mainly in the INL and particles in 
the PLN and surrounding lymphatics. Excised lymph nodes were also imaged (boxes). e) The corresponding 1H/19F MRI, with 19F data in false color, 
also shows the same distribution. The injection site is just outside the field of view. Please see Figure S11 (Supporting Information) for further in vivo 
images, and Figure S12 (Supporting Information) for ex vivo images on a clinical scanner.
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During clinical DC vaccinations, therapeutic cells can be 
injected directly in the lymph nodes of patients.[56] However, 
the total volume of the cells, which is needed for the injec-
tion in the murine lymph nodes of the mice, is too high for 
the intranodal injection (>10 µL). Therefore, we injected nano-
particle solution using the amount of nanoparticles, equiva-
lent to 0.1 × 106 labeled DCs. In comparison, in human trials 
higher cell numbers are used, typically 3–15 × 106 cells injected 
intranodally.[56] High-frequency ultrasound imaging showed 
that the mean contrast of the lymph node changed over tenfold, 
owing to the presence of nanoparticles equivalent to 0.1 × 106 
labeled cells (Figure 6b, and Videos S1 and S2, Supporting 
Information).
Finally, to see if migratory cells could be imaged using US, 
we injected labeled primary murine DCs in vivo in the footpad. 
Control mice were injected with the same number of untreated 
cells or free nanoparticles alone. Mice were imaged 24 h after 
injection using ultrasound, both at a clinical (Figure S12, Sup-
porting Information, ex vivo) and at a high-frequency scanner 
(Figure 6c, and Figure S11, Supporting Information). Lower 
resolution clinical imaging at 7 MHz (Figure S12, Supporting 
Information) was not able to resolve mouse LNs in vivo; thus, 
the nodes were imaged in vivo at 25 MHz on a high-frequency 
preclinical US scanner. Additionally, we imaged the lymph nodes 
ex vivo with both scanners (Figure S12, Supporting Information, 
and Figure 6c) to corroborate the in vivo data. A sixfold increase 
in contrast was observed between nodes that contain nanoparti-
cles or labeled cells, and those with nonlabeled cells (Figure 6c). 
The presence of cells in the lymph nodes was further confirmed 
in the fluorescence and 19F MRI images (Figure 6d,e). In con-
trast to labeled cells, nonlabeled cells were not detectable at any 
point. Typically, around 2% of injected DCs migrate from the 
injection site to draining lymph nodes,[56] which suggests that 
we can detect as little as 0.1 × 106 cells (2% of injected dose). A 
previous study showed that free nanoparticles are cleared from 
the site of injection, allowing for repeated injections.[31] Thus, 
the results presented here confirm that we imaged migratory 
labeled cells reaching a lymph node in vivo, and not free con-
trast nanoparticles or nonlabeled migratory cells. Finally, the 
sensitivity of imaging is well above that necessary for DC vac-
cination trials, and the labeling does not seem to hinder DC 
migration in vivo, demonstrating that these particles are suitable 
for the labeling and imaging of therapeutic cells.
Overall, our in vivo results demonstrate that these nanoparti-
cles are suitable for long-term imaging with ultrasound, 19F MRI, 
and with addition of a dye to the formulation, also fluorescent 
and photoacoustic imaging.[17] Combining these complementary 
imaging techniques allows flexibility in clinical imaging. Thus, 
fast and easy screening with ultrasound at the bedside could 
be combined, for example, with quantitative 19F MRI, perhaps 
followed by fluorescence microscopy in biopsy samples. 19F MRI 
can provide quantitative information but requires more imaging 
time and transport of the patient to an MRI machine. Fluores-
cence provides better resolution, but it is hampered by the lim-
ited penetration of light through biological tissues.
Modern personalised medicine is complex, and there is no 
single imaging agent that can provide all the required informa-
tion (e.g., cost-effective, accessible, penetration depth, quanti-
tative, long-term).[57] Our multimodal imaging agent allows for 
the flexibility to combine the strengths of different imaging 
modalities as needed for a specific imaging need.
3. Conclusion and Outlook
Ultrasound imaging is ideally suited for the study of personal-
ized therapeutics, but its potential is vastly unrealized due to 
the lack of stable, small, and biocompatible agents. Here, we 
present nano-particles (radius 100 nm), which are suitable for 
long-term in vivo ultrasound in combination with 19F MRI and 
fluorescence. The acoustic contrast generation does not involve 
vaporization of PFCE, evidenced by the lack of change in size, 
PFCE content, and the ability to perform 19F MRI after ultra-
sound. The nanoparticles in this study have a very atypical 
fractal structure, with multiple PFCE cores, each of which is 
surrounded by PLGA, as shown by SANS. Additionally, despite 
the hydrophobic nature of PFCE, NMR revealed that water is 
inside the particles and is in contact with the PFCE. This struc-
ture could be a key to the sustained acoustic contrast.
The physicochemical characteristics of fractal PFCE-PLGA 
nanoparticles can be adjusted for additional biomedical applica-
tions.[33] Possible modifications include changes in size or degra-
dation rate, as well as surface modification with targeting ligands 
or a stealth PEG coating for additional applications.[33] Finally, 
these nanoparticles have recently been approved for a pilot 
clinical trial, where they will be used to label therapeutic den-
dritic cells in melanoma patients [NCT02574377]. Future clinical 
translation can be expected and these agents could potentially 
allow radiation-free and real-time ultrasound at bedside in clin-
ical areas now dominated by other imaging modalities.
4. Experimental Section
Statistics: Standard two-tailed t-tests were carried out where indicated. 
In all cases, standard deviations and sample sizes are indicated.
Synthesis: Nanoparticles were made as described previously,[31] 
with or without the addition of gadoteridol from Prohance (Bracco 
Imaging Europe, Amsterdam). PLGA nanoparticles with entrapped 
perfluorocarbon alone or in combination with gadoteridol and a 
fluorescent dye, IC-Green (Akorn Inc., IL, USA) were prepared using 
a miniemulsion formulation method. Briefly, PLGA (100 mg, Resomer 
RG 502 H, lactide: glycolide molar ratio 48:52 to 52:48; Evonic 
Industry, Germany) were dissolved in dichloromethane (3 mL) and 
mixed rapidly with PFCE (900 µL, Exfluor Inc., TX, USA), or (230 µL, 
Perfluoron, Alcon Inc., TX, USA), or PFOB (275 µL, Fluorochem, UK). 
When needed, IC-Green (1 mg) in water and/or gadoteridol (1780 µL) 
were added. This mixture was premixed with a pipette and added 
rapidly to aqueous solution of poly(vinyl alcohol) (25.5 g, 1.96 wt%) 
and emulsified for 3 min under sonication at 40% amplitude using 
a digital sonicator from Branson Ultrasonics (Connecticut, USA). 
The solvent was evaporated overnight at 4 °C under stirring, and 
nanoparticles were collected by centrifugation at 21 000 g for 
20 min, washed five times with distilled water, and lyophilized yielding 
≈100 mg of nanoparticles as a colorless powder. 19F NMR: δ [ppm] 
−92 (CF of PFCE); typical PFCE content 20–40 wt% (33 ± 11 wt% 
(N = 79)); corresponds to 4 × 1019 to 9 × 1018 19F atoms mg−1 
determined with trifluoroacetic acid as internal reference). Gd content 
was measured using inductively coupled plasma mass spectrometry 
(ICP MS). The particles typically contain 0.5 µg mg−1. Depending 
on which batch of commercial PVA is used, the addition of some 
poly(propylene oxide) (PPO, Sigma-Aldrich, average Mn 2700) to 
Adv. Funct. Mater. 2019, 29, 1806485
www.afm-journal.dewww.advancedsciencenews.com
1806485 (10 of 14) © 2019 The Authors. Published by WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
the PLGA-PFCE mixture in dichloromethane (DCM) can improve the 
encapsulation of PFCE. Typically, PPO stock solution in DCM (15 mg 
of stock solution, prepared by adding 80 mg PPO to 150 µL DCM) 
was used. This addition is needed only with some batches of PVA, as 
PPO can be present in PVA as impurity, but the amount is different 
depending on which batch of PVA is used.
Nanocapsules were synthesized using sodium cholate as 
surfactant. PLGA (100 mg, resomer 502H) was dissolved in 
dichloromethane (3 mL) and mixed with perfluoro-15-crown-5 
ether (900 µL) by pipetting it up and down with a glass pipette. 
The resulting primary emulsion was added to solution of sodium 
cholate (25 g, 1.5 wt% solution in water) and sonicated on ice for 
3 min at an amplitude of 40% (Branson digital sonifier s250). After 
sonication, dichloromethane was evaporated overnight under stirring 
at room temperature. To exchange the surfactant, PVA solution (10 g 
of 1.96 wt% solution) was added to the suspension and the mixture 
was stirred at 4 °C for 5 d. The particles were washed twice with water 
at 16 000 g for 35 min. After washing, particles were resuspended in 
water (4 mL), frozen with liquid N2 and freeze-dried. Typical yield: 
≈50–100 mg nanocapsules as a colorless powder. 19F NMR: δ [ppm] 
−92 (CF of PFCE); typical PFCE content 10–20 wt% (determined 
with TFA as internal reference).
Acoustic Properties: The experimental setup used to measure the 
acoustic cross section consisted of a square cross-section capillary 
of about 380 µm in size attached to a piezoelectric crystal in order to 
generate an acoustic standing wave in the capillary at a frequency of 
1.94 MHz. The motion of the particles was recorded at 125 frames s−1 
using a high-speed camera (Photron, APX-RS) connected to an Olympus 
microscope. A 10× microscope objective was used for the visualization. 
The signals were generated with a Tabor AWG arbitrary waveform 
generator and amplified with an ENI 350L power amplifier. The 
experiments were realized at low pressures to limit the rapid build-up 
of acoustic streaming in the fluid. The data analysis was performed in 
Matlab, notably the PIV vector fields were obtained using OpenPIV, a 
freely available software. Two methods were used simultaneously to 
analyze the optical recording to obtain a better precision. The first is a 
PIV analysis based on the cross correlation between a subset of images. 
The relative displacement obtained from the PIV analysis can then 
be rescaled to the known geometry. The second method is based on 
averaging in the horizontal direction. The resulting pixel line was added 
to the previous ones in a single frame as presented in Figure 1f (panels). 
The measurement was done at least three times, with the average and 
standard deviation shown.
The direct measurement of the pressure scattered by the 
nanoparticles is delicate due to the low absolute pressure scattered, 
and the need to use the same transducer for the reception and the 
emission in a controlled environment with sufficient sensitivity. 
Theories indeed predict a high directivity of the signal scattered by solid 
particles, and the same could apply here. Therefore, the acoustic activity 
and echogenicity of the particles was further quantified using a method 
based on acoustic radiation force.[58] The signal backscattered by an US 
contrast agent and the radiation force acting on it have the same origin, 
and therefore a measure of the scattering coefficient can be achieved 
by measuring the particle displacement in a well-defined acoustic 
field. A piezoelectric single element transducer was used to generate 
a standing wave in a square glass capillary with homogeneously 
dispersed particles. The creation of an US standing wave induces 
migration toward the pressure node or antinode located in the middle 
and the sides of the channel, respectively. The motion of the particles 
was recorded with a high-speed camera and analyzed (Figure 1e). To do 
so, each frame was averaged in the direction of the channel to give a 
single pixel line in Matlab. The pixel line from the consecutive’s frames 
was added one after the other to create the time frame presented. 
The convergence observed in the time frame was then compared 
to the theoretical result of the force balance equation to extract the 
corresponding cross section.
Quantification of Scattering Cross Section: The forces acting on a 
random particle in an acoustic field include the drag force,[59] the added 
mass force that describes the acceleration of the surrounding fluid 
following the particle motion,[60] and the radiation force that drives the 
motion of the particle. The force balance equation can then be solved 
to determine the trajectory of the particle of any given size. In first 
approximation, the particles are assumed to obey the well-accepted 
theory describing the interaction of a rigid sphere with the acoustic 
field.[58] A field decomposition of the radiation force into spherical 
harmonics gives a frequency component f1 that only depends on 
the density mismatch and a frequency component f2 that depends on 
the relative compressibility. The radiation force, Fr, experienced by the 
particle in a standing wave is then given by
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Solving the wave equation on a spherical harmonic base leads to the 
following expression for the far-field backscattered scalar potential in a 
spherical referential having its origin at the center of the particle and the 
space variables r and θ
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In a traveling ultrasound wave of the same frequency, the potential 
becomes
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For a solid polymer nanoparticle, the imaginary part of the coefficient 
f2 can then be neglected as compared to the real part. The backscattered 
pressure, ps, then relates to the radiation force in the direction of the 
transducer by
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From this expression, the scattering cross section in intensity can be 
defined as the total scattered power over the incoming intensity
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For these calculations, these following parameters were assumed:
cPFCE = 652 m s−1
cPFOB = 658 m s−1
cPFO = 598 m s−1 (from our pulse-echo data).
The specific gravity of the PFCE is stated by the manufacturer as 1.78.
Attenuation Measurements: For the attenuation measurement, a 
Tabor WW1281A arbitrary waveform generator was used to generate 
the acoustic signal, subsequently amplified by a Vectawave VBA100-200 
amplifier, and sent to a Panametrics A308S transducer (5 MHz center 
frequency, 1.96 in. focal distance). The acoustic wave was allowed to 
propagate through a chamber built in-house (18 mm acoustical path 
length), sealed with two acoustically transparent membranes. The 
transducer was calibrated in emission using an optical hydrophone 
(Precision Acoustics, UK) in order to send a constant pressure across 
the whole frequency range investigated. The transmitted wave was 
then measured by a panametric A305S transducer (2.25 MHz center 
frequency, 1.88 in. focal length). 20 cycle waveforms were sent for each 
set of pressures and frequencies, and the measurement was repeated 
200 times for each parameter set.
Physicochemical Characterization of Nanoparticles: DLS experiments 
were performed on a Malvern Zetasizer ZS Nano at a scattering angle 
θ = 173° using disposable cuvettes. The particle concentration was 
0.01 mg mL−1. The typical hydrodynamic radius obtained at θ = 173° was 
around 100 nm (average over more than ten different batches).
Multiangle DLS and Static LS experiments were performed on 
ALV compact goniometer system equipped with ALV7004 correlator, 
ALV/LSE-5004 Goniometer, ALV/Dual High QE APD detector unit 
with a fiber splitting device setup of two off detection system, and 
a Uniphase Model 1145P He-Ne Laser. The laser wavelength and 
power were 632.8 nm and 22 mW, respectively. The temperature was 
controlled by a Julabo CF41 thermostatic bath. Water for dilutions 
was filtered with 0.45 µm hydrophilic filters. The concentration of 
samples was 0.01 mg mL−1
DLS data were collected at scattering angles θ = 30°–150° in 10° 
steps. Data analysis was done with HDRC software, which was kindly 
provided by Prof. Manfred Schmidt, University of Mainz, Germany. The 
apparent hydrodynamic radii at different angles were obtained either 
from the cumulant or the biexponential fitting of the autocorrelation 
function. Both provided a good approximation of the radius for particles 
with polydisperse, monomodal size distribution. The absolute inverse 
z-averages of hydrodynamic radii were obtained by extrapolating the 
apparent diffusion coefficients q→0.[61,62] The second cumulant values 
µ2 were obtained from cumulant fitting at θ = 90°.
Static light scattering (SLS) for determination of the radius of gyration 
(Rg) was measured at θ = 30°–60° in 3° steps. This measurement range 
was selected, as it is needed for Guinier analysis (q × Rg ≤ 1). The radius 
of gyration was determined from the angular dependence of the Rayleigh 
ratio according to the Guinier equation.[63] The Rayleigh ratio Rθ was 
obtained as follows
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with a refractive index of solvent nwater = 1.333, refractive index 
of reference ntoluene = 1.494, and Rayleigh ratio of toluene 
Rtoluene = 1.02 × 10−3 m−1 calculated as described by Wu.[64]
Nanoparticle density was measured with an oscillating U tube using 
an Anton Paar DMA 5000. Aqueous solutions of nanoparticles with 
weight fractions of nanoparticles w = 0.01, 0.008, 0.005, 0.003, and 0.001 
were used, and the density of solid particles was calculated from a linear 
extrapolation using
11
1
2
2wρ ρ
ρ
ρ ρ= + −
   (10)
Typical density of PFCE and PFOB nanoparticles ranges between 
1.4 and 1.5 mg cm−3.
SEM was done on an environmental scanning electron microscope FEI 
ESEM XL30 at 20 kV and magnifications up to 60 000×. The sample was 
fixed on a glass plate by evaporation of the suspension fluid. A layer of gold 
was then deposited on the sample before observation by SEM was done 
three times on different batches, and representative images are shown.
Cryo-SEM was done at JEOL 6330 Cryo Field Emission Scanning 
Electron Microscope (FESEM). For cryo-SEM analysis, the samples (8 µL, 
10 mg mL−1) were pipetted in two rivets, which were then placed together. 
Next, the samples were frozen in liquid nitrogen slush and placed in 
an Oxford Alto 2500 cryo station with a cryo-transfer device. There the 
top rivet was broken, and the sample was heated to −95 °C for 5 min, 
followed by a coating of 60/40 Au/Pd and transfer to the cryo-SEM.
Nuclear magnetic resonance spectroscopy was measured on Brucker 
Avance III 400 MHz spectrometer equipped with BBFO probe at 298 K. 
Particles (typically 5–8 mg) were dissolved in 500 µL D2O and mixed 
with 1 µL TFA in 100 µL D2O.
2D HOESY was performed using a spectral width spanning from 
−110 to −60 ppm for 19F (377 MHz) and −0.5 to 10.5 ppm for 1H 
(400 MHz) using 2048 × 256 points. 16 scans per increment were 
acquired using an interscan relaxation delay of 2.0 s and a mixing time 
for dipole–dipole relaxation of 400 ms.
Quantitative 19F NMR was measured with an interscan relaxation 
delay of 20 s. The number of scans was between 8 and 32 depending on 
concentration of fluorinated compound.
Data evaluation was done with MestreNova 10.0 from Mestrelab. 
Internal projections of HOESY spectra were extracted using TopSpin 
3.5 from Bruker.
19F solid-state NMR spectra and relaxation times were measured 
on a Varian VNMRS 850 MHz spectrometer. A 4 mm HXY probe was 
used, which was resonant for 19F at a frequency of 799.75 MHz; the 
samples were spun at an magic angle spinning (MAS) frequency of 
10 kHz. A spin echo sequence was used for measuring the T2 relaxation 
time and inversion recovery experiments for T1. For measuring the 
particles in dry state, freeze-dried nanoparticle powder was used. To 
obtain nanoparticles that are swollen with water, freeze-dried powder 
was incubated with excess of water for 5 min and then centrifuged at 
21 000 g. The pellet from centrifugation was then immediately filled 
into a rotor for solid-state NMR measurements. Data evaluation was 
performed with MatNMR.
SANS experiments were performed at the D11 small angle 
diffractometer at the ILL in Grenoble (France). The description of settings 
of D11 diffractometer is given in detail in the Supporting Information. 
SANS was also carried out on the SANS2D small-angle diffractometer at 
the ISIS Pulsed Neutron Source (STFC Rutherford Appleton Laboratory, 
Didcot, UK; http://www.isis.stfc.ac.uk).[65] A collimation length of 12 m 
and incident wavelength range of 1.75–12.5 Å were employed. Data were 
measured simultaneously on two 1 m2 detectors to give a q-range of 
0.0015–0.85 Å−1. The small-angle detector was positioned 12 m from the 
sample and offset vertically 80 mm and sideways 100 mm. The wide-
angle detector was position 5 m from the sample, offset sideways by 
860 mm and rotated to face the sample. The magnitude of the scattering 
wave vector q is defined as
4 sin
2Q
π
θ
λ=
 (11)
where θ is the scattered angle and λ is the incident neutron wavelength. 
The beam diameter was 8 mm. Each raw scattering data set was corrected 
for the detector efficiencies, sample transmission, and background 
scattering and converted to scattering cross-section data (∂Σ/∂Ω vs q) 
using the instrument-specific software (http://www.mantidproject.org). 
These data were placed on an absolute scale (cm−1) using the scattering 
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from a standard sample (a solid blend of hydrogenous and perdeuterated 
polystyrene) in accordance with established procedures.[66]
Samples in D2O and H2O/D2O 36/64 (v:v) were measured in 2 mm 
quartz cuvettes, while for samples in H2O/D2O 61/39 (v:v) 1 mm cuvettes 
were used. In total, five different batches of nanoparticles with and without 
gadoteridol and two different batches were measured. Measurement data 
that were not included in this manuscript is available from the authors.
Data analysis was done using the NIST SANS[67] Macro for Igor Pro 
(Wavemetrics) or SasView 4.1.0.[68]
Imaging Techniques and Cell Labeling: In Vitro Imaging: In vitro US 
imaging was carried out on samples in a gel phantom or injected 
ex vivo in bovine liver tissue. A linear array transducer (L11-3) with 
center frequency 7 MHz was used for all the US scans (SONOS 
7500, Philips Medical Systems, Best, The Netherlands). The MI was 
variable, from 0.1 to 1.2, as stated in the text. Gain was set to 90%. Gel 
phantoms consisted of 8% gelatin (Dr. Oetker, Ede, The Netherlands) 
and 2% agar (Agar Powder CMN, Boom, Meppel, The Netherlands) by 
weight. Analyses on the contrast (Figures 1b,c and 2c) were carried out 
by drawing a region of interest over the relevant area and measuring 
average pixel intensity using Image J (U.S. National Institutes of Health, 
Bethesda, MD).[69] The average intensity is shown (n = 3). Cells were 
labeled with the particles in at least three experiments (with different 
batches of particles and cells from different donors).
For Figure 2a, the particles were exposed to 60 s of US at an MI 
of 1.2 (8 MHz, focus at 0.5 cm; n = 3) before the measurement size 
parameters through DLS. In Figure 2b, the particles were exposed to 
probe sonication for 30 s at 40% power, as during synthesis (n = 3). SEM 
was performed before and after probe sonication. Injections of particles 
in tissue phantoms were done (n = 5) with different batches of particles 
and in different tissue phantoms. 1 mg of particles contains about 
4 × 108 particles mg−1; Sonovue(c) contains about 2 × 108 bubbles mL−1 
when reconstituted as per directions. For Figure 2c, 0.5 mg of particles 
were injected in a tissue phantom. Images were acquired immediately 
after injection at low (0.2) and high (1.2) mechanical index (0 h), and 
the transducer was left on and in place at MI = 1.2 for 80 min (80 min, 
continuous). After 80 min, the phantoms were imaged again at both 
MI. The phantoms were then placed in a freezer for 48 h and thawed at 
room temperature for 1 h, before further imaging (48 h).
MR imaging (Figure 6e) was performed on an 11.7 T MR system 
(Bruker Biospin, Ettlingen, Germany), equipped with a horizontal bore 
magnet, using a dual 1H/19F volume coil. Image settings were TR/TE of 
800/10.5 ms, 2 × 2 × 2 mm voxels, 256 × 128 matrix, and 2 averages for 
1H using a spin echo sequence; 960/46 ms, 4 × 4 × 4 mm voxels, 64 × 32 
matrix, 512 averages using a RARE sequence with RARE factor 8. For 
fluorescence imaging, samples were placed in a FluorVivo 300 (INDEC 
BioSystems, Santa Clara, CA). Exposure times were between 0.05 and 
0.15 s (Figure 6d). Imaging of labeled cells was done with three different 
batches of particles and cells from different donors.
Cell Isolation and Labeling: Primary human DCs were isolated from 
donor blood as previously described[55] and labeled with 5 mg of 
particles per million cells from days 3 to 8 of the in vitro culture period 
(n = 3). Cells were washed three times before use. Viable cells were 
counted using a cell counter with trypan blue exclusion.
Primary murine DCs were generated from bone marrow cells as 
previously described.[70] Cells were incubated with 1 mg of particles per 
million cells mL−1 overnight for labeling (n = 3); 1 µg mL−1 LPS was used 
to obtain mature DCs.
In Vivo Imaging: Mice were housed under specified pathogen-
free conditions in the Central Animal Laboratory (Nijmegen, The 
Netherlands). All experiments were performed according to the 
guidelines for animal care of the Nijmegen Animal Experiments 
Committee. Untreated C57/BL/6J female mice (Harlan) at ten weeks of 
age were used for these experiments; 12 mice were used for imaging, 
with at least three mice per condition, with the experiment repeated 
three times. All mice were identical before experimentation, and thus no 
further randomization procedure was used.
High-resolution in vivo US imaging was carried out using a 
VisualSonics Vevo 2100 system (MS-700 probe, central frequency 
50 MHz, 100% power, gain set to 37 dB). Mice were anesthetized 
using Isoflurane. Intranodal injections (Figure 6b) were performed with 
a NanoFil Microliter syringe (World Precision Instruments, Germany) 
under microscopic guidance (n = 3). For the cell tracking experiments 
(Figure 6c–e), 5 × 106 cells were injected in the footpad of a mouse, and 
the mouse was imaged 24 h later (popliteal and inguinal lymph nodes) 
with high-resolution in vivo US (n = 6) The nodes were also removed and 
imaged ex vivo in a gel at a high (MS-700 probe, VisualSonics Vevo 2100) 
and low frequency (7 MHz, Philips SONOS 7500; n = 2). MRI was carried 
out on a horizontal bore 7T system (Bruker, Clinscan) using a dual-tuned 
volume coil. Image settings were TR/TE of 1200/15 ms, 0.1 × 0.1 × 2 mm 
voxels, 512 × 512 matrix, and 2 averages for 1H using a TSE sequence 
with an acquisition time of 2.57 min; 100/2.8 ms, 1.6 × 0.8 × 4 mm 
voxels, 64 × 32 matrix, 256 averages using a GRE sequence with an 
acquisition time of 13.42 min (n = 2). Fluorescence imaging was done in 
a FluorVivo system, as with the ex vivo tissue samples (n = 6).
Supporting Information
Supporting Information is available from the Wiley Online Library or 
from the author.
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